A Study to Assess the Efficacy and Safety of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in Adults With Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid Leukemia
The primary objective of this study is to evaluate the efficacy of entospletinib (ENTO)
compared to placebo when added to chemotherapy in previously untreated nucleophosmin-1
mutated (NPM1-m) acute myeloid leukemia (AML), as defined by the rate of molecularly define...
Age: 18 - 74 years
Gender: All
A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-486 (ONUREG®) in combination with venetoclax in relapsed and/or refractory Acute Myeloid Leukemia (AML) and newly diagnosed AML.
Age: 18 years - 66+
Gender: All
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
The primary purpose of this study is to determine: the recommended Phase 2 doses (RP2Ds) of
JNJ-64264681 and JNJ 67856633 when administered together in participants with B cell
non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Part A - Dose Escalati...
Age: 18 years - 66+
Gender: All
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to characterize safety and to determine the putative recommended
Phase 2 dose(s) (RP2D[s]) and optimal dosing schedule(s) of JNJ-75348780 in participants with
relapsed/ refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic...
Age: 18 years - 66+
Gender: All
Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
The primary objective of this phase 1b study is to evaluate the safety and tolerability of
blinatumomab and AMG 404 in combination in adults with R/R B-ALL and to estimate the maximum
tolerated dose (MTD) and recommended phase 2 dose (RP2D) of AMG 404 when combined ...
Age: 18 - 99 years
Gender: All
Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
The primary objective of this phase 1b study is to evaluate the safety and tolerability of
blinatumomab and AMG 404 in combination in adults with R/R B-ALL and to estimate the maximum
tolerated dose (MTD) and recommended phase 2 dose (RP2D) of AMG 404 when combined ...
Age: 18 - 99 years
Gender: All
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to determine the safety and feasibility of outpatient
blinatumomab administration for subjects with Minimal Residual Disease of B-precursor Acute
Lymphoblastic Leukemia.
Age: 18 - 99 years
Gender: All
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
: The purpose of this study is to test whether blinatumomab in combination with TKI therapy (such as dasatinib) is an effective treatment for people with Ph+ ALL. Researchers want to improve the response to standard-of-care treatment of corticosteroids + TKI therapy by ...
Age: 18 years - 66+
Gender: All
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
This phase III trial compares standard chemotherapy to therapy with CPX-351 and/or
gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3
mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab
oz...
Age: Birth - 22 years
Gender: All
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
The presence of IDH mutation is associated with worse survival in patients with
myelofibrosis. Moreover IDH mutations are among the most frequently encountered events in
MPNs that have progressed to acute myeloid leukemia. Ruxolitinib, a JAK1/2 inhibitor, and
enas...
Age: 18 years - 66+
Gender: All
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
The presence of IDH mutation is associated with worse survival in patients with myelofibrosis. Moreover IDH mutations are among the most frequently encountered events in MPNs that have progressed to acute myeloid leukemia. Ruxolitinib, a JAK1/2 inhibitor, and enasidenib...
Age: 18 years - 66+
Gender: All
Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
The purpose of this study is to determine whether the combination of pevonedistat +
venetoclax + azacitidine improves event-free survival (EFS) compared with venetoclax +
azacitidine in patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for
i...
Age: 18 years - 66+
Gender: All
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
The purpose of the study is to determine the recommended Phase 2 dose(s) (RP2D[s]) in B cell
non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in Part 1 and to evaluate
the safety of JNJ-64264681 at the RP2D(s) in Part 2.
Age: 18 years - 66+
Gender: All
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, when
administered alone and in combination with low-dose cytarabine (LDAC) or Decitabine for the
treatment of adults with Acute Myeloid Leukemia (AML) and AML secondary to myeloproliferativ...
Age: 18 years - 66+
Gender: All
First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess ziftomenib (KO-539), a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML).
Age: 18 years - 66+
Gender: All
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
This phase III trial studies whether inotuzumab ozogamicin added to post-induction
chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves
outcomes. This trial also studies the outcomes of patients with mixed phenotype acute
l...
Age: 1 year - 24 years
Gender: All
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
This phase III trial studies how well blinatumomab works in combination with chemotherapy in
treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or
B-lymphoblastic lymphoma with or without Down syndrome. Monoclonal antibodies, such as
bl...
Age: 365 days - 31 years
Gender: All
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
The purpose of this study is to determine if a search strategy of searching for an
HLA-matched unrelated donor for allogeneic transplantation if possible then an alternative
donor if an HLA-matched unrelated donor is not available versus proceeding directly to an
...
Age: Birth - 66+
Gender: All
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to determine the recommended Phase 2 dose regimen or the maximum
tolerated dose of JNJ-67856633 in participants with relapsed/ refractory B-cell non-Hodgkin
lymphoma and chronic lymphocytic leukemia.
Age: 18 years - 66+
Gender: All
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
This Phase Ib/II, open-label, multicenter, non-randomized study will evaluate the safety,
efficacy, and pharmacokinetics of idasanutlin when it is given in combination with cytarabine
and daunorubicin in induction, in combination with cytarabine in consolidation, and ...
Age: 18 years - 66+
Gender: All